berk-effectof-2022.pdf (3.5 MB)
Download file

Effect of Glucocorticoid and 11 beta-Hydroxysteroid-Dehydrogenase Type 1 (11 beta-HSD1) in Neurological and Psychiatric Disorders

Download (3.5 MB)
journal contribution
posted on 10.02.2022, 00:00 authored by Seetal Dodd, David SkvarcDavid Skvarc, Olivia DeanOlivia Dean, Anna Anderson, Mark KotowiczMark Kotowicz, Michael BerkMichael Berk
Abstract
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity is implicated as a moderator of the progression of multiple diseases and disorders in medicine and is actively subject to investigation as a therapeutic target. Here we summarize the mechanisms of the enzyme and detail the novel agents under investigation. Such agents modulate peripheral cortisol and cortisone levels in hypertension, type 2 diabetes, metabolic disorders, and Alzheimer’s disease models, but there is mixed evidence for transduction into symptom management. There is inchoate evidence that 11β-HSD1 modulators may be useful pharmacotherapies for clinical improvement in psychiatry and neurology; however, more research is required.

History

Journal

International Journal of Neuropsychopharmacology

Volume

25

Issue

5

Pagination

387 - 398

Publisher

Oxford University Press (OUP)

Location

Oxford, Eng.

ISSN

1461-1457

eISSN

1469-5111

Language

English

Publication classification

C1 Refereed article in a scholarly journal